Collaborative Expansion Merz Therapeutics is actively expanding through partnerships and licensing, notably in Brazil with Grünenthal and in Greater China with Jiangxi Kvvit Pharmaceutical for INBRIJA. This points to opportunities to leverage co-promotion, regional market access, or additional licensing deals to accelerate penetration in high-potential neurology markets.

Parkinsons Focus A core pipeline focus on movement disorders and intermittent OFF episodes in Parkinson's disease, with INBRIJA advancing in Greater China, mainland China, Hong Kong, and Macao. Potential sales opportunities exist in regions with growing PD prevalence and demand for levodopa inhalation therapy, including new market entry support and payer strategies.

Neurology Leadership Strong presence in specialty neurology with active participation in major scientific congresses (ISPRM World Congress 2026) and a program of multiple abstracts. This supports value-based selling through robust clinical evidence and thought leadership to drive physician adoption and payer justification.

Patient Engagement Public-facing campaigns like Celebrating the Fighters underscore a patient-centric branding approach and opportunities for patient advocacy partnerships, community engagement programs, and patient-reformance storytelling to enhance product uptake and adherence initiatives.

Global Footprint Active in over 80 countries with a substantial revenue range and a privately held family ownership heritage. Potential sales angles include global access programs, regional distribution optimization, and strategic partnerships to extend manufacturing and logistics capabilities to new markets.